Since CP therapy has been a prevalent and effective mode of treatment in various viral infections in the past (e.g. Ebola, MERS and SARS-CoV [84]), the WHO is considering it for the control of COVID-19 as well. The gene discussed is CP; the disease is Ebola hemorrhagic fever.